Compare Costco Wholesale Corporation (COST) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Cytokinetics Inc — how do they compare? Costco Wholesale Corporation trades at $926.46 (market cap $408.78B), while Cytokinetics Inc trades at $81.44 (market cap $11.12B). The key difference: Costco Wholesale Corporation is far larger — about 36.8× Cytokinetics Inc's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| COST | CYTK | |
|---|---|---|
Market Cap | $408.78B | $11.12B |
Sector | Consumer Staples | Technology |
52-Week High | $1.09K | $87.26 |
52-Week Low | $849.63 | $33.23 |
Enterprise Value | $396.92B | $11.59B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $920.54, down 0.64% on the day, with a bearish technical signal from moving averages. The company reported revenue of $275.24 billion in 2025, with net income of $8.10 billion, and recently announced strong March sales growth of 11.3% year-over-year (GlobeNewsWire, 2026-04-08). Analyst consensus is strongly bullish with a $1,120 price target, supported by 38 buy ratings.
The stock's high P/E of 46.37 reflects premium valuation, but consistent revenue growth and membership fee increases underpin fundamentals. Risks include competitive pressures and sensitivity to consumer spending. Upside potential exists if the stock pulls back toward support levels, aligning with analyst targets.
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
